Wedbush analysts have lowered their 2029 earnings projection for Revolution Medicines, Inc. (NASDAQ: RVMD) from $1.47 to $1.23 per share. The updated report signals a more reserved stance on the biotech firm’s long-term performance outlook.

A recent note from Zacks Research projects a lower Q3 2026 earnings per share for Lowe’s, dropping the figure to $2.97. The revision underscores a more cautious stance on the home improvement retailer and signals potential concerns for investors.

Zacks Research has lowered its FY2026 earnings forecast for Neogen Corporation from $0.38 to $0.30 per share. The move signals a more cautious view of the company’s potential performance and was reported on August 24, 2025.